Results 51 to 60 of about 964,099 (295)

The Role of the Complement Pathway in Clinical Progression of Geographic Atrophy

Ophthalmology Science, 2023
Purpose: To investigate the relationship between complement pathway activities and progression of geographic atrophy (GA) secondary to age-related macular degeneration in samples collected from patients enrolled in the Chroma and Spectri trials.
Rose Edmonds, MS, Verena Steffen, MSc, Lee A. Honigberg, PhD, Michael C. Chang, PhD   +3 more
doaj   +1 more source

The anabolic steroid stanozolol is a potent inhibitor of human MutT homolog 1

FEBS Letters, EarlyView.
MutT homolog 1 (MTH1) is a member of the NUDIX superfamily of enzymes and is an anticancer drug target. We show that stanozolol (Stz), an anabolic steroid, is an unexpected nanomolar inhibitor of MTH1. The X‐ray crystal structure of the human MTH1–Stz complex reveals a unique binding scaffold that could be utilized for future inhibitor development ...
Emma Scaletti Hutchinson, Robert Gustafsson Westergren, Ingrid Almlöf, Ann‐Sofie Jemth, Martin Scobie, Ulrika Warpman Berglund, Thomas Helleday, Pål Stenmark   +7 more
wiley   +1 more source

Biomarkers of the Dementia [PDF]

International Journal of Alzheimer’s Disease, 2011
Recent advances in biomarker studies on dementia are summarized here. CSF Aβ40, Aβ42, total tau, and phosphorylated tau are the most sensitive biomarkers for diagnosis of Alzheimer′s disease (AD) and prediction of onset of AD from mild cognitive impairment (MCI).
openaire   +2 more sources

The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology

Animals, 2022
The programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) pathway mainly attracted attention in immuno-oncology, leading to the development of immune checkpoint therapy.
Sandra Schöniger, Bharat Jasani
doaj   +1 more source

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

Molecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia, Anouk C. de Jong, Lisanne F. van Dessel, Vanja de Weerd, Corine Beaufort, Jean Helmijr, José Alberto Nakauma‐González, Job van Riet, Paul Hamberg, Daniel Vis, Michiel S. van der Heijden, Nick Beije, Martijn P. Lolkema, Teoman Deger, Saskia M. Wilting, Ronald de Wit, Maurice P. H. M. Jansen, John W. M. Martens   +17 more
wiley   +1 more source

Biomarkers in mesothelioma [PDF]

Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2017
Mesothelioma is an aggressive cancer of pleural and peritoneal cells that is difficult to diagnose and monitor. Numerous studies have attempted to identify a blood- or pleural fluid-based biomarker that could be used in the diagnostic pathway. More recently, there has been interest in the ability of serum/plasma biomarkers to monitor mesothelioma ...
Arnold, David T, Maskell, Nick A
openaire   +5 more sources

Highly multiplexed digital PCR assay for simultaneous quantification of variant allele frequencies and copy number alterations of KRAS and GNAS in pancreatic cancer precursors

Molecular Oncology, EarlyView.
Combining melting curve analysis enhances the multiplexing capability of digital PCR. Here, we developed a 14‐plex assay to simultaneously measure single nucleotide mutations and amplifications of KRAS and GNAS, which are common driver genes in pancreatic cancer precursors. This assay accurately quantified variant allele frequencies in clinical samples
Junko Tanaka, Tatsuo Nakagawa, Yusuke Ono, Yoshio Kamura, Takeshi Ishida, Hidemasa Kawabata, Kenji Takahashi, Hiroki Sato, Andrew S. Liss, Yusuke Mizukami, Takahide Yokoi   +10 more
wiley   +1 more source

Biomarkers in Osteoarthritis [PDF]

HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery, 2012
The future of OA biomarkers is great. The number of studies currently underway has increased greatly, including longitudinal studies. More research on new biomarkers is underway, and we hope to increase awareness and use of biochemical biomarkers over the next few years.
openaire   +3 more sources

A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary

Nature Communications
Cancers of Unknown Primary (CUP) remains a diagnostic and therapeutic challenge due to biological heterogeneity and poor responses to standard chemotherapy.
Alicia-Marie Conway, Simon P. Pearce, Alexandra Clipson, Steven M. Hill, Francesca Chemi, Dan Slane-Tan, Saba Ferdous, A. S. Md Mukarram Hossain, Katarzyna Kamieniecka, Daniel J. White, Claire Mitchell, Alastair Kerr, Matthew G. Krebs, Gerard Brady, Caroline Dive, Natalie Cook, Dominic G. Rothwell   +16 more
doaj   +1 more source

Fine-grained cell-type specific association studies with human bulk brain data using a large single-nucleus RNA sequencing based reference panel

Scientific Reports, 2023
Brain disorders are leading causes of disability worldwide. Gene expression studies provide promising opportunities to better understand their etiology but it is critical that expression is studied on a cell-type level.
Edwin J. C. G. van den Oord, Karolina A. Aberg   +1 more
doaj   +1 more source